Loading...
Loading...
Analysts at Maxim Group downgraded
Tekmira Pharmaceuticals CorpTKMR from Buy to Hold.
The price target for Tekmira Pharmaceuticals has been lowered from $27.00 to $14.00.
Tekmira Pharmaceuticals shares have gained 10.51 percent over the past 52 weeks, while the S&P 500 index has surged 7.33 percent in the same period.
Tekmira Pharmaceuticals' shares closed at $14.93 yesterday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in